Febuxostat  	Febuxostat  	 NNP	B-NP
for  	for  	 IN	O
the  	the  	 DT	O
treatment  	treatment  	 NN	O
of  	of  	 IN	O
hyperuricaemia  	hyperuricaemia  	 NN	B-NP
in  	in  	 IN	O
people  	people  	 NNS	O
with  	with  	 IN	O
gout 	gout 	 NNS	B-NP
:  	:  	 :	O
a  	a  	 DT	O
single  	single  	 JJ	O
technology  	technology  	 NN	B-NP
appraisal  	appraisal  	 VBD	I-NP
This  	This  	 DT	O
paper  	paper  	 NN	O
presents  	presents  	 VBZ	O
a  	a  	 DT	O
summary  	summary  	 NN	O
of  	of  	 IN	O
the  	the  	 DT	O
evidence  	evidence  	 NN	B-NP
review  	review  	 NN	I-NP
group  	group  	 NN	I-NP
( 	( 	 -LRB-	O
ERG 	ERG 	 NNP	O
)  	)  	 -RRB-	O
report  	report  	 NN	O
into  	into  	 IN	O
the  	the  	 DT	O
clinical  	clinical  	 JJ	B-NP
effectiveness  	effectiveness  	 NN	I-NP
and  	and  	 CC	O
cost-effectiveness  	cost-effectiveness  	 JJ	B-NP
of  	of  	 IN	I-NP
febuxostat  	febuxostat  	 NN	I-NP
for  	for  	 IN	O
the  	the  	 DT	O
management  	management  	 NN	O
of  	of  	 IN	O
hyperuricaemia  	hyperuricaemia  	 NN	B-NP
in  	in  	 IN	O
patients  	patients  	 NNS	O
with  	with  	 IN	O
gout  	gout  	 VBG	B-NP
based  	based  	 VBN	O
upon  	upon  	 IN	O
a  	a  	 DT	O
review  	review  	 NN	O
of  	of  	 IN	O
the  	the  	 DT	O
manufacturer 	manufacturer 	 NN	O
's  	's  	 POS	O
submission  	submission  	 NN	O
to  	to  	 TO	O
the  	the  	 DT	O
National  	National  	 NNP	O
Institute  	Institute  	 NNP	O
for  	for  	 IN	O
Health  	Health  	 NNP	O
and  	and  	 CC	O
Clinical  	Clinical  	 NNP	B-NP
Excellence  	Excellence  	 NNP	I-NP
( 	( 	 -LRB-	O
NICE 	NICE 	 NNP	O
)  	)  	 -RRB-	O
as  	as  	 IN	O
part  	part  	 NN	O
of  	of  	 IN	O
the  	the  	 DT	O
single  	single  	 JJ	B-NP
technology  	technology  	 NN	I-NP
appraisal  	appraisal  	 NN	I-NP
( 	( 	 -LRB-	O
STA 	STA 	 NNP	B-NP
)  	)  	 -RRB-	O
process 	process 	 NN	O
.  	.  	 .	O
The  	The  	 DT	O
submission 	submission 	 NN	O
's  	's  	 POS	O
evidence  	evidence  	 NN	O
came  	came  	 VBD	O
from  	from  	 IN	O
two  	two  	 CD	O
randomised  	randomised  	 NNS	O
controlled  	controlled  	 VBN	B-NP
trials  	trials  	 NNS	I-NP
comparing  	comparing  	 VBG	O
the  	the  	 DT	O
efficacy  	efficacy  	 NN	O
and  	and  	 CC	O
safety  	safety  	 NN	O
of  	of  	 IN	O
febuxostat  	febuxostat  	 NN	B-NP
with  	with  	 IN	O
allopurinol 	allopurinol 	 NN	B-NP
.  	.  	 .	O
The  	The  	 DT	O
trials  	trials  	 NNS	O
were  	were  	 VBD	O
of  	of  	 IN	O
reasonable  	reasonable  	 JJ	O
methodological  	methodological  	 JJ	B-NP
quality  	quality  	 NN	I-NP
and  	and  	 CC	O
measured  	measured  	 VBN	O
a  	a  	 DT	O
clinically  	clinically  	 JJ	O
relevant  	relevant  	 JJ	O
range  	range  	 NN	O
of  	of  	 IN	O
outcomes 	outcomes 	 NNS	O
.  	.  	 .	O
A  	A  	 DT	O
pooled  	pooled  	 JJ	O
clinical  	clinical  	 JJ	B-NP
efficacy  	efficacy  	 JJ	I-NP
analysis  	analysis  	 NN	I-NP
showed  	showed  	 VBD	O
that  	that  	 IN	O
a  	a  	 DT	O
daily  	daily  	 JJ	O
dose  	dose  	 NN	O
of  	of  	 IN	O
80  	80  	 CD	O
mg  	mg  	 NNS	B-NP
or  	or  	 CC	O
120  	120  	 CD	O
mg  	mg  	 NN	B-NP
of  	of  	 IN	I-NP
febuxostat  	febuxostat  	 NN	I-NP
was  	was  	 VBD	O
significantly  	significantly  	 RB	O
more  	more  	 RBR	O
effective  	effective  	 JJ	O
than  	than  	 IN	O
fixed-dose  	fixed-dose  	 JJ	B-NP
allopurinol  	allopurinol  	 NNS	I-NP
( 	( 	 -LRB-	O
300 	300 	 CD	O
/ 	/ 	 CD	O
100  	100  	 CD	O
mg 	mg 	 CD	B-NP
/ 	/ 	 CD	I-NP
day 	day 	 NN	I-NP
)  	)  	 -RRB-	O
at  	at  	 IN	O
lowering  	lowering  	 VBG	B-NP
serum  	serum  	 JJ	I-NP
uric  	uric  	 JJ	I-NP
acid  	acid  	 NN	I-NP
( 	( 	 -LRB-	O
sUA 	sUA 	 NNP	B-NP
)  	)  	 -RRB-	O
levels  	levels  	 NNS	O
to  	to  	 TO	O
therapeutic  	therapeutic  	 JJ	B-NP
targets  	targets  	 NNS	I-NP
(  	(  	 -LRB-	O
< 	< 	 SYM	O
6  	6  	 CD	O
mg 	mg 	 CD	B-NP
/ 	/ 	 CD	I-NP
dl 	dl 	 CD	I-NP
) 	) 	 -RRB-	O
;  	;  	 :	O
however 	however 	 RB	O
,  	,  	 ,	O
a  	a  	 DT	O
large  	large  	 JJ	O
percentage  	percentage  	 NN	O
of  	of  	 IN	O
febuxostat  	febuxostat  	 JJ	B-NP
patients  	patients  	 NNS	I-NP
did  	did  	 VBD	O
not  	not  	 RB	O
achieve  	achieve  	 VB	O
the  	the  	 DT	O
primary  	primary  	 JJ	B-NP
end  	end  	 NN	I-NP
point  	point  	 NN	I-NP
and  	and  	 CC	O
the  	the  	 DT	O
fixed-dose  	fixed-dose  	 JJ	B-NP
allopurinol  	allopurinol  	 JJ	I-NP
regimen  	regimen  	 NN	I-NP
may  	may  	 MD	O
have  	have  	 VB	O
introduced  	introduced  	 VBN	B-NP
bias 	bias 	 NN	I-NP
.  	.  	 .	O
There  	There  	 EX	O
were  	were  	 VBD	O
no  	no  	 DT	O
differences  	differences  	 NNS	O
between  	between  	 IN	O
treatments  	treatments  	 NNS	O
in  	in  	 IN	O
more  	more  	 RBR	O
clinically  	clinically  	 JJ	O
important  	important  	 JJ	O
outcomes  	outcomes  	 JJ	O
such  	such  	 JJ	O
as  	as  	 IN	O
gout  	gout  	 JJ	O
flares  	flares  	 NN	O
and  	and  	 CC	O
tophi  	tophi  	 JJ	B-NP
resolution  	resolution  	 NN	I-NP
after  	after  	 IN	O
52  	52  	 CD	O
weeks  	weeks  	 NNS	O
of  	of  	 IN	O
treatment 	treatment 	 NN	O
.  	.  	 .	O
No  	No  	 DT	O
subgroup  	subgroup  	 JJ	B-NP
analyses  	analyses  	 NNS	I-NP
were  	were  	 VBD	O
conducted  	conducted  	 VBN	O
for  	for  	 IN	O
patients  	patients  	 NNS	O
with  	with  	 IN	O
renal  	renal  	 JJ	B-NP
impairment 	impairment 	 NN	I-NP
,  	,  	 ,	O
non-responders  	non-responders  	 JJ	B-NP
to  	to  	 TO	O
allopurinol  	allopurinol  	 VB	O
or  	or  	 CC	O
patients  	patients  	 NNS	O
with  	with  	 IN	O
severe  	severe  	 JJ	O
disease 	disease 	 NN	O
.  	.  	 .	O
Supplementary  	Supplementary  	 JJ	O
data  	data  	 NNS	O
from  	from  	 IN	O
a  	a  	 DT	O
2-year  	2-year  	 JJ	O
open-label  	open-label  	 JJ	B-NP
extension  	extension  	 NN	I-NP
study  	study  	 NN	I-NP
were  	were  	 VBD	O
also  	also  	 RB	O
provided 	provided 	 VBN	O
,  	,  	 ,	O
but  	but  	 CC	O
were  	were  	 VBD	O
difficult  	difficult  	 JJ	O
to  	to  	 TO	O
interpret  	interpret  	 VB	O
and  	and  	 CC	O
poorly  	poorly  	 RB	O
reported 	reported 	 VBD	O
.  	.  	 .	O
The  	The  	 DT	O
incidence  	incidence  	 NN	O
of  	of  	 IN	O
adverse  	adverse  	 JJ	O
events  	events  	 NNS	O
was  	was  	 VBD	O
similar  	similar  	 JJ	O
between  	between  	 IN	O
treatments 	treatments 	 NNS	O
,  	,  	 ,	O
although  	although  	 IN	O
more  	more  	 RBR	O
febuxostat  	febuxostat  	 JJ	B-NP
recipients  	recipients  	 NNS	I-NP
discontinued  	discontinued  	 VBN	I-NP
treatment  	treatment  	 NN	I-NP
prematurely 	prematurely 	 RB	O
.  	.  	 .	O
A  	A  	 DT	O
decision  	decision  	 NN	B-NP
tree  	tree  	 NN	I-NP
model  	model  	 NN	I-NP
was  	was  	 VBD	O
developed  	developed  	 VBN	O
to  	to  	 TO	O
determine  	determine  	 VB	O
the  	the  	 DT	O
cost-effectiveness  	cost-effectiveness  	 JJ	B-NP
of  	of  	 IN	I-NP
febuxostat 	febuxostat 	 NN	I-NP
.  	.  	 .	O
The  	The  	 DT	O
scope  	scope  	 NN	O
was  	was  	 VBD	O
limited  	limited  	 VBN	O
to  	to  	 TO	O
the  	the  	 DT	O
comparison  	comparison  	 NN	O
of  	of  	 IN	O
continual  	continual  	 JJ	B-NP
febuxostat  	febuxostat  	 JJ	I-NP
treatment  	treatment  	 NN	I-NP
with  	with  	 IN	O
continual  	continual  	 JJ	B-NP
allopurinol  	allopurinol  	 JJ	I-NP
treatment 	treatment 	 NN	I-NP
.  	.  	 .	O
Switching  	Switching  	 VBG	O
between  	between  	 IN	O
treatments  	treatments  	 NNS	O
or  	or  	 CC	O
withdrawing  	withdrawing  	 JJ	O
treatment  	treatment  	 NN	O
in  	in  	 IN	O
patients  	patients  	 NNS	O
whose  	whose  	 WP$	O
sUA  	sUA  	 JJ	B-NP
levels  	levels  	 NNS	I-NP
had  	had  	 VBD	O
not  	not  	 RB	O
decreased  	decreased  	 VBN	O
was  	was  	 VBD	O
not  	not  	 RB	O
permitted 	permitted 	 VBN	O
.  	.  	 .	O
The  	The  	 DT	O
model  	model  	 NN	O
predicted  	predicted  	 VBD	O
a  	a  	 DT	O
cost-effectiveness  	cost-effectiveness  	 JJ	B-NP
of  	of  	 IN	O
16,324  	16,324  	 CD	O
pounds  	pounds  	 NNS	O
[ 	[ 	 -LRB-	O
95 	95 	 CD	O
%  	%  	 NN	O
confidence  	confidence  	 NN	B-NP
interval  	interval  	 NNS	I-NP
( 	( 	 -LRB-	O
CI 	CI 	 NNP	O
)  	)  	 -RRB-	O
6281  	6281  	 CD	O
pounds  	pounds  	 NNS	O
to  	to  	 TO	O
239,928  	239,928  	 CD	O
pounds 	pounds 	 NNS	O
]  	]  	 -RRB-	O
per  	per  	 FW	O
quality-adjusted  	quality-adjusted  	 FW	B-NP
life-year  	life-year  	 FW	I-NP
( 	( 	 -LRB-	O
QALY 	QALY 	 NNP	B-NP
)  	)  	 -RRB-	O
gained  	gained  	 VBD	O
for  	for  	 IN	O
febuxostat  	febuxostat  	 VBG	O
compared  	compared  	 VBN	O
with  	with  	 IN	O
allopurinol  	allopurinol  	 NN	B-NP
after  	after  	 IN	O
2  	2  	 CD	O
years  	years  	 NNS	O
of  	of  	 IN	O
treatment 	treatment 	 NN	O
.  	.  	 .	O
The  	The  	 DT	O
incremental  	incremental  	 JJ	B-NP
cost  	cost  	 NN	I-NP
per  	per  	 IN	O
QALY  	QALY  	 NNP	B-NP
was  	was  	 VBD	O
below  	below  	 IN	O
20,000  	20,000  	 CD	O
pounds  	pounds  	 NNS	O
in  	in  	 IN	O
63 	63 	 CD	O
%  	%  	 NN	O
of  	of  	 IN	O
the  	the  	 DT	O
simulations  	simulations  	 JJ	O
undertaken 	undertaken 	 NN	O
.  	.  	 .	O
Changes  	Changes  	 NNS	O
in  	in  	 IN	O
the  	the  	 DT	O
time  	time  	 NN	B-NP
horizon  	horizon  	 NN	I-NP
did  	did  	 VBD	O
not  	not  	 RB	O
materially  	materially  	 RB	O
affect  	affect  	 VB	O
the  	the  	 DT	O
results 	results 	 NNS	O
.  	.  	 .	O
The  	The  	 DT	O
ERG  	ERG  	 NNP	O
believes  	believes  	 VBZ	O
that  	that  	 IN	O
the  	the  	 DT	O
modelling  	modelling  	 JJ	O
structure  	structure  	 NN	O
employed  	employed  	 NNS	O
was  	was  	 VBD	O
not  	not  	 RB	O
appropriate  	appropriate  	 JJ	O
to  	to  	 TO	O
estimate  	estimate  	 VB	O
the  	the  	 DT	O
cost-effectiveness  	cost-effectiveness  	 JJ	B-NP
of  	of  	 IN	I-NP
febuxostat  	febuxostat  	 NN	I-NP
within  	within  	 IN	O
a  	a  	 DT	O
treatment  	treatment  	 NN	B-NP
algorithm 	algorithm 	 NN	I-NP
.  	.  	 .	O
In  	In  	 IN	O
addition 	addition 	 NN	B-NP
,  	,  	 ,	O
there  	there  	 EX	O
were  	were  	 VBD	O
concerns  	concerns  	 NNS	O
about  	about  	 IN	O
the  	the  	 DT	O
methodology  	methodology  	 NN	O
used  	used  	 VBN	O
for  	for  	 IN	O
collecting  	collecting  	 VBG	O
data  	data  	 NNS	O
on  	on  	 IN	O
key  	key  	 JJ	B-NP
model  	model  	 NN	I-NP
inputs 	inputs 	 NNS	I-NP
.  	.  	 .	O
Given  	Given  	 VBN	O
these  	these  	 DT	O
reservations  	reservations  	 NNS	B-NP
the  	the  	 DT	O
cost-effectiveness  	cost-effectiveness  	 JJ	B-NP
of  	of  	 IN	I-NP
febuxostat  	febuxostat  	 NNS	I-NP
could  	could  	 MD	O
not  	not  	 RB	O
be  	be  	 VB	O
determined 	determined 	 VBN	O
.  	.  	 .	O
The  	The  	 DT	O
guidance  	guidance  	 NN	O
issued  	issued  	 VBN	O
by  	by  	 IN	O
NICE  	NICE  	 NNP	O
in  	in  	 IN	O
August  	August  	 NNP	O
2008  	2008  	 CD	O
as  	as  	 IN	O
a  	a  	 DT	O
result  	result  	 NN	O
of  	of  	 IN	O
the  	the  	 DT	O
STA  	STA  	 NNP	B-NP
states  	states  	 NNS	I-NP
that  	that  	 IN	O
febuxostat  	febuxostat  	 NN	B-NP
is  	is  	 VBZ	O
recommended  	recommended  	 VBN	O
as  	as  	 IN	O
an  	an  	 DT	O
option  	option  	 NN	O
for  	for  	 IN	O
the  	the  	 DT	O
management  	management  	 NN	O
of  	of  	 IN	O
chronic  	chronic  	 JJ	B-NP
hyperuricaemia  	hyperuricaemia  	 NN	I-NP
in  	in  	 IN	O
gout  	gout  	 VBG	B-NP
only  	only  	 RB	O
for  	for  	 IN	O
people  	people  	 NNS	O
who  	who  	 WP	O
are  	are  	 VBP	O
intolerant  	intolerant  	 VBN	O
of  	of  	 IN	O
allopurinol  	allopurinol  	 NN	B-NP
or  	or  	 CC	O
for  	for  	 IN	O
whom  	whom  	 WP	O
allopurinol  	allopurinol  	 RB	O
is  	is  	 VBZ	O
contraindicated 	contraindicated 	 VBN	O
.  	.  	 .	O
